Cite
HARVARD Citation
Scher, H. et al. (n.d.). 444 Presence of AR-V7 splice variant or AR C terminal loss in the CTCs of mCRPC patients identifies patients with improved PSA response with taxanes over androgen receptor signaling directed therapies (ARS Rx). European journal of cancer. pp. S93-. [Online].